Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days

Rhea-AI Summary

BOSTON, March 28, 2023 – Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company, announced that CEO Laurence Reid, Ph.D., will participate in a fireside chat at the Guggenheim Healthcare Talks on April 3, 2023, at 9:00 a.m. E.T. in New York, NY. The event will focus on genomic medicines and rare diseases. Investors can access a live webcast from Decibel's website, with a replay available for 90 days after the event. Decibel Therapeutics aims to develop treatments for hearing and balance disorders, leveraging a proprietary platform that includes gene therapy technologies and expertise in inner ear biology.

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 9:00 a.m. E.T in New York, NY.

A live webcast of the presentation may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936

FAQ

What is Decibel Therapeutics' stock symbol?

Decibel Therapeutics is traded under the stock symbol DBTX.

When will Laurence Reid speak at the Guggenheim Healthcare Talks?

Laurence Reid will participate in the fireside chat on April 3, 2023, at 9:00 a.m. E.T.

Where can I watch the webcast of the Decibel Therapeutics presentation?

The webcast can be accessed via the Investors section of Decibel Therapeutics' website.

What is the focus of Decibel Therapeutics?

Decibel Therapeutics is focused on developing treatments for hearing and balance disorders.

How long will the webcast replay be available after the event?

The replay of the webcast will be available for approximately 90 days following the event.